GeekWireFor cancer patients with HIV, immunotherapy appears safeMedical XpressA new category of immunotherapies called checkpoint inhibitors that has been highly effective against many different cancers appears safe to use in patients with both advance… Continue reading
Scope (blog)Stanford researchers grow neural stem cells more efficiently in 3-D gelScope (blog)Stem cells have the potential to help us understand and treat a range of diseases and injuries — from vision loss to cancers. For instance, a Japanese man in… Continue reading
Gene Therapy in Recurrent Glioma Shows Promise in Early TrialCancer NetworkMore than 25% of patients with recurrent, high-grade glioma treated with a gene therapy combination were alive more than 3 years after treatment, according to data from a subset… Continue reading
Gene Therapy in Recurrent Glioma Shows Promise in Early TrialCancer NetworkMore than 25% of patients with recurrent, high-grade glioma treated with a gene therapy combination were alive more than 3 years after treatment, according to data from a subset… Continue reading
Biodesix Oral Presentation At SITC: Testing Methodology May Identify Primary Immunotherapy Resistance In PatientsGlobeNewswire (press release)“Not all patients respond to immunotherapies,” said Dr. Heinrich Roder. “The pre-treatment circulating proteom… Continue reading
Medical Xpress |
A ‘CRISPR‘ view of Sturge-Weber syndrome is coming into focus
Medical Xpress Three-dimensional modeling and CRISPR-Cas9 gene editing technology are giving scientists a new view into Sturge-Weber syndrome, a rare congenital disorder that causes small blood vessels, called capillaries, to be malformed. These capillary … |
Medical Xpress |
A ‘CRISPR‘ view of Sturge-Weber syndrome is coming into focus
Medical Xpress Three-dimensional modeling and CRISPR-Cas9 gene editing technology are giving scientists a new view into Sturge-Weber syndrome, a rare congenital disorder that causes small blood vessels, called capillaries, to be malformed. These capillary … |
Philadelphia Business Journal |
Spark, Pfizer amend agreement for experimental hemophilia gene therapy
Philadelphia Business Journal Under the amended agreement, Spark Therapeutics, a Philadelphia gene therapy company spun out of Children’s Hospital of Philadelphia, will enroll up to five additional participants in the current phase-I/II clinical trial testing the treatment known as … Spark Therapeutics (ONCE), Pfizer (PFE) Amend Pact for Investigational SPK-9001 in Hemophilia BStreetInsider.com |